Brii Bio has reported topline EOT data from its ongoing Phase IIb ENRICH and ENHANCE trials assessing sequential and concurrent use of BRII-179, elebsiran, and PEG-IFNα to treat chronic HBV infection. The post Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studies appeared first on Clinical Trials Arena .